The Pearsanta’s MET diagnostic test uses a blood-based biomarker for detecting mitochondrial DNA for diagnosing endometriosis ...

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, ...

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its majority-owned subsidiary, Pearsanta Inc., have signed a market development collaboration ...

Aditxt (NASDAQ: ADTX) , an innovation platform dedicated to accelerating promising health innovations, has reported that its Acquisition target, Evofem Biosciences (OTCQB: EVFM) , a women's health ...

Under the Agreement, Evofem and Pearsanta will collaboratively develop a comprehensive go-to-market strategy and MET commercial plan ahead of the planned U.S. launch in mid-2025. To date, over 300 ...

Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising <a target=_blank href= ...

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see a ...